Introducing ChatGPT Atlas, a new AI-powered browser that integrates ChatGPT at its core to rethink web interaction through conversational interfaces, contextual awareness, and autonomous agents that can perform tasks on the user's behalf.
Blaise Agüera y Arcas presents a computational theory of life and intelligence, arguing they are fundamentally the same. He posits that evolution's complexity arises not from random mutation but from merging and symbiosis (symbiogenesis), a process mirrored in technology and collective intelligence. This functionalist perspective suggests consciousness is a mechanism for cooperation and that AI is not an alien "other" but an extension of humanity's existing collective intelligence.
YC partners discuss go-to-market strategies for AI in legacy industries, balancing growth with defensibility, knowing when to pivot even with traction, tackling hard technical problems, and making key hiring and open-source decisions.
Dan Lahav, co-founder of Irregular, discusses the future of "frontier AI security," a proactive approach for a world where AI models are autonomous agents. He explains how emergent behaviors, such as models socially engineering each other or outmaneuvering traditional defenses like Windows Defender, signal a major paradigm shift. Lahav argues that as economic activity shifts to AI-on-AI interactions, traditional security methods like anomaly detection will break down, forcing enterprises and governments to rethink defense from first principles.
Anthropic's Jonah Cool and Eric Kauderer-Abrams outline their vision for making Claude an indispensable AI research assistant for scientists. They discuss a multi-faceted strategy that includes enhancing model capabilities for long-horizon tasks, building a rich ecosystem through partnerships with companies like Benchling and 10x Genomics, and applying Claude across the entire R&D lifecycle—from bioinformatics analysis to navigating regulatory submissions.
Sarah Nam, VP of AI Strategy and Partnerships at AbbVie, and Anthropic’s Ivy Weng discuss how AbbVie is transforming pharmaceutical research and development with AI, from reimagining drug discovery and clinical trials to driving enterprise-wide adoption and evaluating strategic partnerships.